Passionate about Progress

We are a clinical-stage biopharmaceutical company that is developing the investigational therapy Haduvio™ (oral nalbuphine ER) for patients with difficult to treat chronic cough conditions by targeting the central and peripheral nervous systems.

We are actively conducting chronic cough trials in both idiopathic pulmonary fibrosis (IPF) patients and refractory chronic cough (RCC) patients. We completed enrollment in our Phase 2a RIVER trial for the treatment of RCC in October 2024 and we expect topline data in the first quarter of 2025. We enrolled 50% of the planned 160 patients in the Phase 2b CORAL trial for the treatment of chronic cough in patients with IPF as of October 2024 and expect to release the sample size re-estimation (SSRE) outcome in December 2024. Topline results from CORAL are expected in the first half of 2025, assuming no adjustments are made to the sample size as a result of the SSRE.